UniQure Wins First FDA RMAT in Huntington’s Disease After Strong Phase I/II Data

UniQure Wins First FDA RMAT in Huntington’s Disease After Strong Phase I/II Data

Submitted by admin on July 9, 2024 - 11:51am
Source: 
BioSpace
News Tags: 
uniQure
AMT-130
Huntington's disease
clinical trials
Headline: 
UniQure Wins First FDA RMAT in Huntington’s Disease After Strong Phase I/II Data
snippet: 

UniQure on Tuesday released updated Phase I/II data for its investigational gene therapy AMT-130, which significantly slowed disease progression in patients with Huntington’s disease.

Do Not Allow Advertisers to Use My Personal information